Merck & Company Inc (MRK)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $364.26B
Last updated: Nov 17, 2026 at 11:06 AM ET
Merck & Company Inc (MRK) Earnings: Report Dates and Results
Merck & Company (MRK) is expected to report earnings on Feb 2, 2027. In the quarter ended Sep 30, 2026, Merck & Company reported EPS of $2.49, above the $2.12 estimate. It beat the EPS estimate in each of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
MRK has an expected report date of Feb 2, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 13.7% below the $2.04 reported for the quarter ended Dec 31, 2025.
MRK Earnings Call
The latest MRK earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, MRK beat 35, missed 3 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $18.09B, up 4.7% from $17.28B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $2.49 | $2.12 | $1.80 - $2.26 | +17.45% | Beat | -3.5% | 18 | 1 up, 7 down | Oct 29, 2026 | $18.09B |
| Jun 30, 2026 | -$0.13 | -$0.26 | -$0.40 - -$0.03 | +50.00% | Beat | -106.1% | 18 | 0 up, 0 down | Aug 4, 2026 | $16.61B |
| Mar 31, 2026 | -$1.28 | -$1.47 | -$1.81 - -$0.83 | +12.93% | Beat | -157.7% | 20 | 6 up, 7 down | Apr 30, 2026 | $16.29B |
| Dec 31, 2025 | $2.04 | $2.01 | $1.97 - $2.11 | +1.49% | Beat | +18.6% | 17 | 1 up, 8 down | Feb 3, 2026 | $16.40B |
| Sep 30, 2025 | $2.58 | $2.35 | $2.29 - $2.47 | +9.79% | Beat | +64.3% | 18 | 3 up, 5 down | Oct 30, 2025 | $17.28B |
| Jun 30, 2025 | $2.13 | $2.03 | $1.88 - $2.17 | +4.93% | Beat | -6.6% | 17 | 4 up, 8 down | Jul 29, 2025 | $15.81B |
| Mar 31, 2025 | $2.22 | $2.14 | $2.08 - $2.25 | +3.74% | Beat | +7.2% | 16 | 5 up, 3 down | Apr 24, 2025 | $15.53B |
| Dec 31, 2024 | $1.72 | $1.67 | $1.59 - $1.85 | +2.99% | Beat | +5633.3% | 15 | 1 up, 9 down | Feb 4, 2025 | $15.62B |
| Sep 30, 2024 | $1.57 | $1.57 | $1.33 - $1.85 | 0.00% | In line | -26.3% | 15 | 0 up, 2 down | Oct 31, 2024 | $16.66B |
| Jun 30, 2024 | $2.28 | $2.14 | $2.03 - $2.24 | +6.54% | Beat | N/A | 16 | 6 up, 0 down | Jul 30, 2024 | $16.11B |
| Mar 31, 2024 | $2.07 | $1.92 | $1.76 - $2.12 | +7.81% | Beat | +47.9% | 17 | 3 up, 4 down | Apr 25, 2024 | $15.78B |
| Dec 31, 2023 | $0.03 | -$0.11 | -$0.17 - -$0.02 | +127.27% | Beat | -98.1% | 18 | 3 up, 3 down | Feb 1, 2024 | $14.63B |
| Sep 30, 2023 | $2.13 | $1.95 | $1.69 - $1.96 | +9.23% | Beat | +15.1% | 17 | 6 up, 1 down | Oct 26, 2023 | $15.96B |
| Jun 30, 2023 | -$2.06 | -$2.18 | -$2.32 - -$1.99 | +5.50% | Beat | -210.2% | 18 | 0 up, 9 down | Aug 1, 2023 | $15.04B |
| Mar 31, 2023 | $1.40 | $1.34 | $1.20 - $1.46 | +4.48% | Beat | -34.6% | 19 | 7 up, 2 down | Apr 27, 2023 | $14.49B |
| Dec 31, 2022 | $1.62 | $1.54 | $1.48 - $1.74 | +5.19% | Beat | -10.0% | 19 | 7 up, 0 down | Feb 2, 2023 | $13.83B |
| Sep 30, 2022 | $1.85 | $1.71 | $1.55 - $1.86 | +8.19% | Beat | +5.7% | 17 | 4 up, 3 down | Oct 27, 2022 | $14.96B |
| Jun 30, 2022 | $1.87 | $1.71 | $1.57 - $1.80 | +9.36% | Beat | +42.7% | 16 | 6 up, 2 down | Jul 28, 2022 | $14.59B |
| Mar 31, 2022 | $2.14 | $1.83 | $1.55 - $2.09 | +16.94% | Beat | +52.9% | 16 | 6 up, 2 down | Apr 28, 2022 | $15.90B |
| Dec 31, 2021 | $1.80 | $1.52 | $1.22 - $1.66 | +18.42% | Beat | +36.4% | 17 | 3 up, 1 down | Feb 3, 2022 | $13.52B |
| Sep 30, 2021 | $1.75 | $1.55 | $1.36 - $1.67 | +12.90% | Beat | +0.6% | 12 | N/A | Oct 28, 2021 | $13.15B |
| Jun 30, 2021 | $1.31 | $1.35 | $1.18 - $1.41 | -2.96% | Miss | -4.4% | 12 | N/A | Jul 29, 2021 | $11.40B |
| Mar 31, 2021 | $1.40 | $1.61 | $1.55 - $1.75 | -13.04% | Miss | -6.7% | 15 | N/A | Apr 29, 2021 | $10.63B |
| Dec 31, 2020 | $1.32 | $1.39 | $1.29 - $1.49 | -5.04% | Miss | +13.8% | 16 | N/A | Feb 4, 2021 | $9.18B |
| Sep 30, 2020 | $1.74 | $1.43 | $1.19 - $1.55 | +21.68% | Beat | +15.2% | 14 | N/A | Oct 27, 2020 | $10.93B |
| Jun 30, 2020 | $1.37 | $1.09 | $0.70 - $1.24 | +25.69% | Beat | +5.4% | 13 | N/A | Jul 31, 2020 | $9.35B |
| Mar 31, 2020 | $1.50 | $1.34 | $1.16 - $1.44 | +11.94% | Beat | +23.0% | 14 | N/A | Apr 28, 2020 | $12.06B |
| Dec 31, 2019 | $1.16 | $1.15 | $1.10 - $1.19 | +0.87% | Beat | +11.5% | 14 | N/A | Feb 5, 2020 | $4.15B |
| Sep 30, 2019 | $1.51 | $1.24 | $1.17 - $1.28 | +21.77% | Beat | +26.9% | 13 | N/A | Oct 29, 2019 | $12.40B |
| Jun 30, 2019 | $1.30 | $1.16 | $1.09 - $1.20 | +12.07% | Beat | +22.6% | 12 | N/A | Jul 30, 2019 | $11.76B |
| Mar 31, 2019 | $1.22 | $1.05 | $1.01 - $1.10 | +16.19% | Beat | +16.2% | 12 | N/A | Apr 30, 2019 | $10.82B |
| Dec 31, 2018 | $1.04 | $1.03 | $1.00 - $1.08 | +0.97% | Beat | +6.1% | 11 | N/A | Feb 1, 2019 | $11.00B |
| Sep 30, 2018 | $1.19 | $1.14 | $1.10 - $1.19 | +4.39% | Beat | +7.2% | 12 | N/A | Oct 25, 2018 | $10.79B |
| Jun 30, 2018 | $1.06 | $1.03 | $1.00 - $1.05 | +2.91% | Beat | +5.0% | 13 | N/A | Jul 27, 2018 | $10.46B |
| Mar 31, 2018 | $1.05 | $1.00 | $0.95 - $1.10 | +5.00% | Beat | +19.3% | 16 | N/A | May 1, 2018 | $10.04B |
| Dec 31, 2017 | $0.98 | $0.94 | $0.90 - $0.96 | +4.26% | Beat | +10.1% | 17 | N/A | Feb 2, 2018 | $10.43B |
| Sep 30, 2017 | $1.11 | $1.03 | $0.99 - $1.08 | +7.77% | Beat | +3.7% | 16 | N/A | Oct 27, 2017 | $10.32B |
| Jun 30, 2017 | $1.01 | $0.87 | $0.85 - $0.90 | +16.09% | Beat | +8.6% | 16 | N/A | Jul 28, 2017 | $9.93B |
| Mar 31, 2017 | $0.88 | $0.83 | N/A | +6.02% | Beat | -1.1% | N/A | N/A | May 2, 2017 | $9.43B |
| Dec 31, 2016 | $0.89 | $0.89 | N/A | 0.00% | In line | -4.3% | N/A | N/A | Feb 2, 2017 | $10.12B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $8.97, up 17.4% from the year before. It was $3.78 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $8.97 | +17.4% |
| Dec 31, 2024 | $7.64 | +409.3% |
| Dec 31, 2023 | $1.50 | -79.9% |
| Dec 31, 2022 | $7.48 | +19.5% |
| Dec 31, 2021 | $6.26 | +5.6% |
| Dec 31, 2020 | $5.93 | +14.3% |
| Dec 31, 2019 | $5.19 | +19.6% |
| Dec 31, 2018 | $4.34 | +9.0% |
| Dec 31, 2017 | $3.98 | +5.3% |
| Dec 31, 2016 | $3.78 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,500 words across 18 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,483 | 18 | |
| 2026Q2 | Jun 30, 2026 | 6,338 | 17 | |
| 2026Q1 | Mar 31, 2026 | 7,039 | 17 | |
| 2025Q4 | Dec 31, 2025 | 8,538 | 16 | |
| 2025Q3 | Sep 30, 2025 | 7,646 | 17 | |
| 2025Q2 | Jun 30, 2025 | 9,349 | 19 | |
| 2025Q1 | Mar 31, 2025 | 8,792 | 16 | |
| 2024Q4 | Dec 31, 2024 | 8,976 | 18 |
2026Q3 Earnings Call
Opening remarks
Peter Dannenbaum Senior Vice President of Investor Relations Thank you, Julie, and good morning, everyone. Welcome to the third-quarter 2026 conference call for Merck & Co., Inc., Rahway, New Jersey, USA. Speaking on today's call will be Robert Davis, Chairman and Chief Executive Officer; Caroline Litchfield, Chief Financial Officer; and Dr. Dean Y. Li, President of Merck Research Labs. Before we get started, I would like to point out that we have items in our GAAP results, such as acquisition-related charges, restructuring costs, and certain other items, that we have excluded from our non-GAAP results. There is a reconciliation in our press release. I will also remind you that some of the statements that we make may be considered forward-looking statements within the meaning of the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 2000. Such statements are made based on the current beliefs of our company's management and are subject to significant risks and uncertainties. If our underlying assumptions prove inaccurate or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Our SEC filings, including Item 1A in the 10-Ks, identify certain risk factors and cautionary statements that could cause the company's actual results to differ materially from those projected in any of our forward-looking statements made this morning. Merck & Co., Inc., Rahway, New Jersey, USA, undertakes no obligation to publicly update any forward-looking statements. During today's call, a slide presentation will accompany our speakers' prepared remarks. These slides, along with the earnings release, today's prepared remarks, and our SEC filings, are all posted to the Investor Relations section of our company's website. With that, I would like to turn the call over to Robert.
Robert Davis Chairman and Chief Executive Officer Thank you, Peter. Good morning, and thank you for joining today's call. 2026 continues to be a year of substantial progress for our company. We are executing well on all fronts, demonstrated particularly by the many new product launches now successfully underway and the important clinical milestones we are achieving that are further derisking the substantial long-term opportunity of our late-phase pipeline. This momentum extends across multiple therapeutic areas and modalities, and there is much more to come, with numerous significant readouts still to occur over the coming years. I am very pleased with how the disciplined execution of our strategy over the past several years is increasingly translating into meaningful clinical, regulatory, and commercial results. The breadth of these achievements strengthens my confidence in the future of our company and our ability to deliver long-term value for patients and shareholders. Turning to our third-quarter results, we delivered solid performance with revenue of $18.1 billion, reflecting increased contributions from new products, as well as strength in oncology and animal health.
Frequently Asked Questions About MRK
When is Merck & Company's next earnings date?
Merck & Company's next earnings report is expected for Feb 2, 2027.
Did MRK beat earnings estimates last quarter?
Yes. Merck & Company reported EPS of $2.49 for the quarter ended Sep 30, 2026, above the $2.12 estimate, a 17.45% surprise.
What EPS do analysts expect from MRK next quarter?
The consensus EPS estimate for Merck & Company for the quarter ending Dec 31, 2026 is $1.76 from 19 analysts, with estimates from $1.67 to $2.01.
How often does MRK beat earnings estimates?
Merck & Company beat the EPS estimate in each of the last 8 quarters, with an average surprise of +12.91%.
MRK pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts